Home/Filings/4/0001479290-20-000082
4//SEC Filing

Rankin Aubrey 4

Accession 0001479290-20-000082

CIK 0001479290other

Filed

Jul 26, 8:00 PM ET

Accepted

Jul 27, 7:57 PM ET

Size

13.5 KB

Accession

0001479290-20-000082

Insider Transaction Report

Form 4
Period: 2020-07-23
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
  • Award

    Common Stock

    2020-07-23+610,041610,041 total
  • Award

    Employee Stock Option (Right to Buy)

    2020-07-23$2.54/sh+8,867$22,5228,867 total
    Exercise: $2.54Exp: 2029-12-19Common Stock (8,867 underlying)
  • Award

    Employee Stock Option (Right to Buy)

    2020-07-23$2.54/sh+44,828$113,86344,828 total
    Exercise: $2.54Exp: 2029-05-13Common Stock (44,828 underlying)
  • Award

    Common Stock

    2020-07-23+57,251667,292 total
Holdings
  • Common Stock

    (indirect: By Trust)
    174,302
  • Common Stock

    (indirect: By Foundation)
    87,151
Footnotes (6)
  • [F1]On July 23, 2020, the Issuer completed acquisition (the "Merger") of Hint, Inc ("HintMD"), pursuant to that certain Agreement and Plan of Merger, dated as of May 18, 2020, by and among the Issuer, Heart Merger Sub, Inc., direct wholly-owned subsidiary of the Issuer, HintMD, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by Mr. Rankin in HintMD were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
  • [F2]The Shares subject to the Restricted Stock award vest as follows: 25% on the first anniversary of the vesting commencement date of August 15, 2020, 25% on the second anniversary of the vesting commencement date of August 15, 2020, and 50% on the third anniversary of the vesting commencement date of August 15, 2020, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) as of each such vesting date.
  • [F3]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
  • [F4]These shares are held by the Rankin Family Foundation. Mr. Rankin is a Trustee of the Rankin Family Foundation.
  • [F5]The Option shall vest as follows: 1/48th of the total number of shares subject to the Option shall vest in 48 equal monthly installments over 4 years beginning from May 1, 2019, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan (the "Plan")) as of each such vesting date.
  • [F6]The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of January 1, 2020, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Rankin's Continuous Service (as defined in the Plan) as of such date.

Issuer

Revance Therapeutics, Inc.

CIK 0001479290

Entity typeother

Related Parties

1
  • filerCIK 0001818576

Filing Metadata

Form type
4
Filed
Jul 26, 8:00 PM ET
Accepted
Jul 27, 7:57 PM ET
Size
13.5 KB